Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Christopher Schott
JPMorgan Chase & Co, Research Division

Good morning, everybody. I’m Chris Schott from JPMorgan and welcome to the 44th Annual JPMorgan Healthcare Conference. It’s great to see everybody today.

So it’s my pleasure to be again — to be introducing Bristol-Myers to again kick off the conference this year. From the company, we have Chairman and CEO, Chris Boerner. Chris is going to do a quick presentation and then we’re going to go to a fireside format from there. So with that, we’ll turn it over to Chris. Happy New Year and looking forward to the presentation. Thanks, Chris.

Christopher Boerner
CEO & Chairman

Thank you, Chris, for the introduction, and it is fantastic to be back kicking off another JPMorgan Healthcare Conference. Obviously, we’re going to be making some forward-looking statements today, so these are my disclosures.

Let me start with just a reminder of our overarching goal as a company. We remain focused on building a company that’s strong financially and has the substrate to deliver industry-leading sustainable growth heading into the 2030s and beyond. Before discussing 2026 and the road ahead, let me start by quickly highlighting the progress we made against that goal last year. 2025 was a year that was focused on execution. And we have made meaningful progress across a number of different fronts. Our growth portfolio increased 17% in the first 9 months of the year. And remember, this is a portfolio that is designed to be comprised of multiple differentiated products that are earlier in their life cycle, so they have a long runway ahead of them.